Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms

Lu ZHANG; Ye LI; Qingqing WANG; Shenghao LI

doi:10.12259/j.issn.2095-610X.S20240601

Volume 45 Issue 6

Jul. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(6): 1-6

Lu ZHANG, Ye LI, Qingqing WANG, Shenghao LI. Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms[J]. Journal of Kunming Medical University, 2024, 45(6): 1-6. doi: 10.12259/j.issn.2095-610X.S20240601

Citation:

Lu ZHANG, Ye LI, Qingqing WANG, Shenghao LI. Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms[J]. Journal of Kunming Medical University, 2024, 45(6): 1-6. doi: 10.12259/j.issn.2095-610X.S20240601

Citation:

PDF( 1855 KB)

Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms

doi: 10.12259/j.issn.2095-610X.S20240601

Lu ZHANG¹,
Ye LI¹,
Qingqing WANG^{1, 2
,
,},
Shenghao LI^{1, 2
,
,}

1.
The Public Health College of Dali University，Dali Yunnan 671000
2.
Dept. of Hepatology，The 3rd People’s Hospital of Kunming，Kunming Yunnan 650041，China

More Information

Corresponding author: 李生浩，医学博士，副主任医师，昆明市第三人民医院肝病综合科主任，大理大学硕士研究生导师。兴滇英才计划-青年人才；云南省高层次卫生科技人才-医学学科后备人才；春城计划-青年拔尖人才；昆明市卫健委“百工程”专家；昆明市官渡区学术和技术带头人；第五届全国疑难及重症肝病攻关协作组(CNSLD)全国委员；中国人口文化促进会肿瘤患者关爱工作委员会委员；第二届中国医药教育协会肝病专业委员会委员；第一届云南省预防医学会健康传播分会常委；第二届云南省医学会感染病分会第十届委员会委员及青年委员会委员；第三届云南省医师协会感染科医师分会委员会委员；云南省医院协会肝病专业委员会委员；第一届云南省抗癌协会肝癌专业委员会委员；昆明市传染性疾病医疗质量控制中心专家委员会委员。主持国家自然科学基金1项，主持或参与省市局级课题10余项。
Received Date: 2024-03-18
Available Online: 2024-05-23
Publish Date: 2024-06-25

Abstract

Abstract

Cirrhosis has a high global incidence rate and serious harm. Numerous studies have shown that liver cirrhosis may cause cardiovascular abnormalities in patients, which are closely related to the severity of the condition and may have adverse effects on the prognosis of liver cirrhosis patients. Therefore, the pathogenesis and research progress in hyperdynamic circulation, portal hypertension pulmonary hypertension, cardiac systolic and diastolic dysfunction, cardiac electrophysiologic abnormalities, and cirrhotic cardiomyopathy are reviewed. To lay the foundation for further in-depth research on the prevention and treatment strategies of liver cirrhosis.
- Cirrhosis,
- Cardiovascular system,
- Portal Hypertension,
- Mechanism

FullText(HTML)

References(48)

References

[1]	Kowalski H J,Abelmann W H. The cardiac output at rest in Laennec's cirrhosis[J]. J Clin Invest,1953,32(10):1025-1033.
[2]	吕少诚,高沿航,王磊,等. 肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识[J]. 临床肝胆病杂志,2021,37(9):2037-2044.
[3]	SimonettoI D A,Liu M,Kamath P S. Portal hypertension and related complications: Diagnosis and management[J]. Mayo Clin Proc,2019,94(4):714-726. doi: 10.1016/j.mayocp.2018.12.020
[4]	战俊邑,刘成海,慕永平. 肝硬化门静脉高压症的中西医结合诊疗研究进展[J]. 上海中医药杂志,2023,57(08):11-15.
[5]	Whipple A O. The problem of portal hypertension in relation to the hepatosplenopathies[J]. Ann Surg,1945,122(4):449-475. doi: 10.1097/00000658-194510000-00001
[6]	Groszmann R J,Abraldes J G. Portal hypertension: From bedside to bench[J]. J Clin Gastroenterol,2005,39(4):125-130.
[7]	Huang C T,Du R Y,Leng X S. Humoral mechanism in pathogenesis of portal hypertension[J]. Chin Med J (Engl),1982,95(6):409-416.
[8]	戚晓亮,郑磊,阿卜杜喀迪尔·图尔荪,等. 肝硬化门静脉高压症发病机制的研究进展[J]. 肝胆胰外科杂志,2023,35(5):311-315.
[9]	Møller S,汤善宏. 肝硬化动脉血管扩张与高动力循环状态的病理生理机制[J]. 临床肝胆病杂志,2017,33(12):2365.
[10]	Møller S,Henriksen J H,Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects[J]. World J Gastroenterol,2014,20(42):15499-15517. doi: 10.3748/wjg.v20.i42.15499
[11]	Iwakiri Y,Kim M Y. Nitric oxide in liver diseases[J]. Trends Pharmacol Sci,2015,36(8):524-536. doi: 10.1016/j.tips.2015.05.001
[12]	Tarquini R,Masini E,LaVilla G,et al. Hepato-systemic gradient of carbon monoxide in cirrhosis[J]. Eur J Intern Med,2012,23(1):14-18. doi: 10.1016/j.ejim.2011.10.008
[13]	Liu DJ,Chen W,Huo Y M,et al. Prostacyclin decreases splanchnic vascular contractility in cirrhotic rats[J]. Hepatobiliary Pancreat Dis Int,2014,13(4):416-422. doi: 10.1016/S1499-3872(14)60270-8
[14]	刘杰凡,刘巍,孙勇伟. 过氧化氢在肝硬化门静脉高压症内脏高动力循环中的作用[J]. 肝胆胰外科杂志,2014,26(6):479-482.
[15]	Iwakiri Y,Groszmann R J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule[J]. Hepatology,2006,43(2 Suppl 1): 121-131.
[16]	Atsukawa M,Tsubota A,Kondo C,et al. Risk factors for portopulmonary hypertension in patients with cirrhosis: A prospective,multicenter study[J]. Hepatol Int,2023,17(1):139-149. doi: 10.1007/s12072-022-10456-y
[17]	Thomas C,Glinshii V,Perez V J,et al. Portopulmonary hypertension: From bench to bedside[J]. Front Med (Lausanne),2020,3(7):569413.
[18]	Rodriguez-Vilarrupla A,Fernandez M,Bosch J,et al. Current concepts on the pathophysiology of portal hypertension[J]. Ann Hepatol,2007,6(1):28-36. doi: 10.1016/S1665-2681(19)31950-7
[19]	Raevens S,Geerts A,VanSteenkiste C,et al. Hepatopulmonary syndrome and portopulmonary hypertension: Recent knowledge in pathogenesis and overview of clinical assessment[J]. Liver Int,2015,35(6):1646-1660. doi: 10.1111/liv.12791
[20]	Pousada G,Baloira A,Valverde D. Mutational screening in genes related with porto-pulmonary hypertension: An analysis of 6 cases[J]. Med Clin (Barc),2017,148(7):310-313. doi: 10.1016/j.medcli.2017.01.020
[21]	Nikolic I,Yung L M,Yang P,et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension[J]. Am J Respir Crit Care Med,2019,199(7):891-902. doi: 10.1164/rccm.201807-1236OC
[22]	Kawut S M,Krowka M J,Trotter J F,et al. Clinical risk factors for portopulmonary hypertension[J]. Hepatology,2008,48(1):196-203. doi: 10.1002/hep.22275
[23]	Terao M,Takaki A,Maruyama T,et al. Serum oxidative/anti-oxidative stress balance is dysregulated in potentially pulmonary hypertensive patients with liver cirrhosis: A case control study[J]. Intern Med,2015,54(22):2815-2826. doi: 10.2169/internalmedicine.54.4889
[24]	Stundiene I,Sarnelyte J,Norkute A,et al. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review[J]. World J Gastroenterol,2019,25(32):4779-4795. doi: 10.3748/wjg.v25.i32.4779
[25]	Lee S K,Song M J,Kim S H,et al. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis[J]. Clin Mol Hepatol,2018,24(4):409-416. doi: 10.3350/cmh.2018.0034
[26]	Schenider H,Berliner D,Stockhoff L,et al. Diastolic dysfunction is associated with cardiac decompensation after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis[J]. United European Gastroenterol J,2023,11(9):837-851. doi: 10.1002/ueg2.12471
[27]	Kovacs A,Scheoke M,Heller J,et al. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: Preliminary results[J]. Cardiovasc Intervent Radiol,2010,33(2):290-296. doi: 10.1007/s00270-009-9696-2
[28]	Bi S,Jiang Y,Zhao W,et al. The predictive value of revised diastolic dysfunction in outcomes of liver transplantation: A propensity score matching analysis[J]. Front Surg,2022,6(9):1072908.
[29]	Timoh T,Protano M A,Wagman G,et al. A perspective on cirrhotic cardiomyopathy[J]. Transplant Proc,2011,43(5):1649-1653. doi: 10.1016/j.transproceed.2011.01.188
[30]	Moller S,Henriksen J H. Cirrhotic cardiomyopathy[J]. J Hepatol,2010,53(1):179-190. doi: 10.1016/j.jhep.2010.02.023
[31]	Ma T,Lin S,Wang B,et al. TRPC3 deficiency attenuates high salt-induced cardiac hypertrophy by alleviating cardiac mitochondrial dysfunction[J]. Biochem Biophys Res Commun,2019,519(4):674-681. doi: 10.1016/j.bbrc.2019.09.018
[32]	Wu G,Liu J,Wang S,et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy[J]. Heart,2021,107(19):1576-1583. doi: 10.1136/heartjnl-2020-317701
[33]	Akhtar H,AlSudani H,Hussein M,et al. Effects of renin-angiotensin-aldosterone system inhibition on left ventricular hypertrophy,diastolic function,and functional status in patients with hypertrophic cardiomyopathy: A systematic review[J]. Cureus,2022,14(7):26642.
[34]	Glenn T K,Honar H,Liu H,et al. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats[J]. J Hepatol,2011,55(6):1249-1255. doi: 10.1016/j.jhep.2011.02.030
[35]	Dourakis S P,Geladari E,Geladari C,et al. Cirrhotic cardiomyopathy: The interplay between liver and cardiac muscle. How does the cardiovascular system react when the liver is diseased?[J]. Curr Cardiol Rev,2021,17(1):78-84. doi: 10.2174/1573403X15666190509084519
[36]	Yoon K T,Liu H,Lee S S. Cirrhotic cardiomyopathy[J]. Curr Gastroenterol Rep,2020,22(9):45. doi: 10.1007/s11894-020-00783-1
[37]	Rajesh M,Mukhopadhyay P,Batkai S,et al. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction,inflammation,oxidative stress,and fibrosis[J]. Geroscience,2022,44(3):1727-1741. doi: 10.1007/s11357-022-00565-9
[38]	Denaes T,Lodder J,Chobert M N,et al. The cannabinoid receptor 2 protects against alcoholic liver disease via a macrophage autophagy-dependent pathway[J]. Sci Rep,2016,27(6):28806.
[39]	Joseph L C,Reyes M V,Lakkadi K R,et al. PKCδ causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction[J]. Am J Physiol Heart Circ Physiol,2020,318(4):778-786. doi: 10.1152/ajpheart.00749.2019
[40]	Liu H,Yoon K T,Zhang J,et al. Advances in cirrhotic cardiomyopathy[J]. Curr Opin Gastroenterol,2021,37(3):187-193. doi: 10.1097/MOG.0000000000000733
[41]	Jude B,Vetel S,Giroux-Metges M A,et al. Rapid negative inotropic effect induced by TNF-α in rat heart perfused related to PKC activation[J]. Cytokine,2018,107(7):65-69.
[42]	Hela E,Sofien K,Kamel L,et al. QT interval abnormalities and heart rate variability in patients with cirrhosis[J]. Arab J Gastroenterol,2020,21(4):246-252. doi: 10.1016/j.ajg.2020.08.001
[43]	Ou M,Tian Y,Zhuang G,et al. QTc interval prolongation in liver cirrhosis with upper gastrointestinal bleeding[J]. Med Clin (Barc),2021,156(2):68-75. doi: 10.1016/j.medcli.2020.06.059
[44]	Papadopoulos V P,Mimdiis K. Corrected QT interval in cirrhosis: A systematic review and meta-analysis[J]. World J Hepatol,2023,15(9):1060-1083. doi: 10.4254/wjh.v15.i9.1060
[45]	Koshy A N,Gow P J,Testro A,et al. Relationship between QT interval prolongation and structural abnormalities in cirrhotic cardiomyopathy: A change in the current paradigm[J]. Am J Transplant,2021,21(6):2240-2245. doi: 10.1111/ajt.16500
[46]	Razpotnik M,Bota S,Wimmer P,et al. The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria[J]. Liver Int,2021,41(5):1058-1069. doi: 10.1111/liv.14769
[47]	An J,Shim J H,Kim S O,et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study[J]. Circulation,2014,130(16):1353-1362. doi: 10.1161/CIRCULATIONAHA.114.009278
[48]	Khandait H,Jaiswal V,Hanif M,et al. Percutaneous coronary intervention outcomes in patients with liver cirrhosis: A systematic review and meta-analysis[J]. J Cardiovasc Dev Dis,2023,10(3):92.

Relative Articles(20)

Relative Articles

[1]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[2]	Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711
[3]	Min ZHOU, Zhihui MA, Jiayan LI, Jianhua FAN, Ling LIN, Tingying YU, Huifang ZHANG, Li LIU. Predictive Model of Risk Factors for the Recurrence of Liver Cirrhosis with Pleural Effusion. Journal of Kunming Medical University, 2022, 43(5): 149-154. doi: 10.12259/j.issn.2095-610X.S20220524
[4]	Qingqing WANG, Jie DING, Hongjie YANG, Guoji CHANG, Siqi LIU, Lijuan HUA, Yiying WANG, Shenghao LI. Predictive Value of RDW and Blood Lipid on Gastroesophageal Variceal Bleeding in Patients with Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(5): 144-148. doi: 10.12259/j.issn.2095-610X.S20220509
[5]	Peizheng XIANG, Mengli LI, Yan FU. Value of Multiple Scoring Systems in Evaluating the Prognosis of Liver Cirrhosis Complicated with Esophageal and Gastric Varices Bleeding. Journal of Kunming Medical University, 2022, 43(3): 128-134. doi: 10.12259/j.issn.2095-610X.S20220316
[6]	Jiang Ming Yuan , Huang Hua , Lu Ming Liang , Ding Wen Jing , Wang Jia Ping , Zheng Su Yun , Shi Xin . . Journal of Kunming Medical University, 2020, 41(02): 32-36.
[7]	Tang Bang Li . Therapeutic Effects and Mechanism of Umbilical Cord Derived Mesenchymal Stem Cell Transplantation for Lupus Nephritis. Journal of Kunming Medical University,
[8]	Jia Nan Nan . Effect of Gnaq on the Proliferation of SH-SY5Y Cells and Its Mechanism of Action. Journal of Kunming Medical University,
[9]	Dong Zhong Li . Monocytes/Macrophages Promote Venous Thrombosis Organization and Recanalization：Mechanism and Research Progress. Journal of Kunming Medical University,
[10]	Kang Du Fu . . Journal of Kunming Medical University,
[11]	Ji Hong . . Journal of Kunming Medical University,
[12]	Zhang Ying Ying . . Journal of Kunming Medical University,
[13]	Li Wei Hua . . Journal of Kunming Medical University,
[14]	Yang Yong Rui . . Journal of Kunming Medical University,
[15]	Shao Jian Lin . . Journal of Kunming Medical University, 2012, 33(04): 1-2.
[16]	Wang Yun . . Journal of Kunming Medical University,
[17]	. Differential Diagnosis of Thrombus in Portal Vein System from Cancer Embolus by CT. Journal of Kunming Medical University,
[18]	. Retrospective Analysis on Glucolipid Metabolism of 64 Patients with Liver Cirrhosis after Treatment with Recombinant Growth Hormone. Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	. The Treatment of Liver Cirrhosis Complicated with Portal Hypertension by Transjugalar Intrahepatic Portosystemic Shunt (a Follow-up Study of 126 Cases). Journal of Kunming Medical University,